First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors
INCAGN02385 exhibited linear PK and preliminary evidence of disease control in this heavily pretreated population, consistent with other LAG-3-targeting monotherapies. A 350-mg Q2W dose was selected for phase II studies that will focus on combinations of INCAGN02385 with other ICIs.
Authors
- Martin Gutierrez (ORCID: https://orcid.org/0000-0003-3156-3159)
- Omid Hamid (ORCID: https://orcid.org/0000-0002-8238-4655)
- Nawel Bourayou
- Ani Sarkis Balmanoukian
- Zhiwan Dong (ORCID: https://orcid.org/0009-0003-9853-2338)
- John D. Powderly (ORCID: https://orcid.org/0000-0002-7608-0380)
- Xuejun Chen (ORCID: https://orcid.org/0000-0002-1568-4383)
- Lulu Cheng (ORCID: https://orcid.org/0000-0002-4984-1279)
- Paul Hoyle
- John E. Janik (ORCID: https://orcid.org/0000-0001-9208-9660)
Institutions
- Hackensack University Medical Center (US)
- Carolina BioOncology Institute (US)
- Angeles Clinic and Research Institute (US)
- Incyte (United States) (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-05-15
- DOI
- https://doi.org/10.1093/oncolo/oyaf136
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.14
Funders
- Incyte